Growth Metrics

Biogen (BIIB) Depreciation & Amortization (CF) (2016 - 2026)

Biogen has reported Depreciation & Amortization (CF) over the past 18 years, most recently at $204.4 million for Q1 2026.

  • For Q1 2026, Depreciation & Amortization (CF) rose 11.57% year-over-year to $204.4 million; the TTM value through Mar 2026 reached $801.1 million, up 13.01%, while the annual FY2025 figure was $779.9 million, 15.85% up from the prior year.
  • Depreciation & Amortization (CF) for Q1 2026 was $204.4 million at Biogen, up from $200.2 million in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $204.4 million in Q1 2026 and troughed at $112.3 million in Q1 2023.
  • A 5-year average of $157.1 million and a median of $147.5 million in 2024 define the central range for Depreciation & Amortization (CF).
  • Biggest five-year swings in Depreciation & Amortization (CF): fell 21.52% in 2023 and later soared 46.24% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $119.8 million in 2022, then increased by 16.94% to $140.1 million in 2023, then surged by 31.33% to $184.0 million in 2024, then grew by 8.8% to $200.2 million in 2025, then increased by 2.1% to $204.4 million in 2026.
  • Business Quant data shows Depreciation & Amortization (CF) for BIIB at $204.4 million in Q1 2026, $200.2 million in Q4 2025, and $202.2 million in Q3 2025.